Ventilator-associated pneumonia in adults: a narrative review
By L. Papazian, M. Klompas, C. Luyt. Intensive Care Medicine, 2020
776 citations recorded by the source corpus.
Ventilator-associated pneumonia (VAP) is one of the most frequent ICU-acquired infections. Reported incidences vary widely from 5 to 40% depending on the setting and diagnostic criteria. VAP is associated with prolonged duration of mechanical ventilation and ICU stay. The estimated attributable mortality of VAP is around 10%, with higher mortality rates in surgical ICU patients and in patients with mid-range severity scores at admission. Microbiological confirmation of infection is strongly encouraged. Which sampling method to use is still a matter of controversy. Emerging microbiological tools will likely modify our routine approach to diagnosing and treating VAP in the next future. Prevention of VAP is based on minimizing the exposure to mechanical ventilation and encouraging early liberation. Bundles that combine multiple prevention strategies may improve outcomes, but large randomized trials are needed to confirm this. Treatment should be limited to 7 days in the vast majority of the cases. Patients should be reassessed daily to confirm ongoing suspicion of disease, antibiotics should be narrowed as soon as antibiotic susceptibility results are available, and clinicians should consider stopping antibiotics if cultures are negative.
Subfields: Biomedical Engineering, Critical Care and Intensive Care Medicine, Epidemiology
View Paper: https://www.semanticscholar.org/paper/7de23cad9452ec2550382be40504aae0975091cf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Critical Care and Intensive Care Medicine
In Epidemiology
Citations in the corpus
- Global incidence and mortality of severe fungal disease. (2024, methodology): “32,33 A baseline estimate has been applied to avoid including years with severe influenza outbreaks and COVID-19 cases, which have a higher overall incidence of invasive aspergillosis.”